Drug Trial Radar · NCT07268040
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Dec 23, 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.
Conditions
- Malignant Solid Tumors
Interventions
SHR-7787 InjectionDrug
SHR-7787 Injection.
SHR-1316 InjectionDrug
SHR-1316 Injection.
SHR-4849 InjectionDrug
SHR-4849 Injection.
Etoposide injectionDrug
Etoposide Injection.
Carboplatin injectionDrug
Carboplatin Injection.
Cisplatin injectionDrug
Cisplatin Injection.
BP102 InjectionDrug
BP102 Injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Recommended phase II dose of SHR-7787 injection monotherapy (stage I)Time frame: Expected to be two years after the start of the study.
- Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (stage I)Time frame: About 1 year after study initiation.
- Incidence and severity of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (stage I)Time frame: About 1 year after study initiation.
- Incidence of Dose Limited Toxicity (DLT) described in the protocol (stage I)Time frame: About 1 year after study initiation.
- Objective response rate (ORR) (stage II)Time frame: Expected to be two years after the start of the study.
- Progress Free Survival (FPS) (stage II)Time frame: Expected to be two years after the start of the study.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.